Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers
- Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study.
- MYMD-1 is being evaluated for autoimmune and age-related diseases.
- The new findings indicate the potential of MYMD-1 to limit the fibrotic biology associated with idiopathic pulmonary fibrosis. MYMD-1 demonstrated inhibition of transforming growth factor-beta, a driver for fibrosis, and tumor necrosis factor, associated with inflammation.
- MyMD plans to move forward in testing combinations of MyMD-1 with approved fibrosis drugs.
- In November last year, Akers Biosciences and MyMD announced a merger agreement.
- Price Action: AKER is down 9.8% at $3.12 in market trading hours on the last check Tuesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: autoimmune diseasesBiotech M&A News Penny Stocks Health Care FDA General
